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ABSTRACT
Background Bintrafusp alfa is a first- in- class bifunctional 
fusion protein composed of the extracellular domain of 
transforming growth factor (TGF)-βRII (a TGF-β ‘trap’) 
fused to a human IgG1 mAb blocking programmed cell 
death ligand 1. This is the largest analysis of patients 
with advanced, pretreated human papillomavirus (HPV)- 
associated malignancies treated with bintrafusp alfa.
Methods In these phase 1 (NCT02517398) and phase 
2 trials (NCT03427411), 59 patients with advanced, 
pretreated, checkpoint inhibitor- naive HPV- associated 
cancers received bintrafusp alfa intravenously every 2 
weeks until progressive disease, unacceptable toxicity, or 
withdrawal. Primary endpoint was best overall response 
per Response Evaluation Criteria in Solid Tumors (RECIST) 
V.1.1; other endpoints included safety.
Results As of April 17, 2019 (phase 1), and October 
4, 2019 (phase 2), the confirmed objective response 
rate per RECIST V.1.1 in the checkpoint inhibitor- naive, 
full- analysis population was 30.5% (95% CI, 19.2% to 
43.9%; five complete responses); eight patients had stable 
disease (disease control rate, 44.1% (95% CI, 31.2% to 
57.6%)). In addition, three patients experienced a delayed 
partial response after initial disease progression, for a 
total clinical response rate of 35.6% (95% CI, 23.6% 
to 49.1%). An additional patient with vulvar cancer had 
an unconfirmed response. Forty- nine patients (83.1%) 
experienced treatment- related adverse events, which were 
grade 3/4 in 16 patients (27.1%). No treatment- related 
deaths occurred.
Conclusion Bintrafusp alfa showed clinical activity 
and manageable safety and is a promising treatment in 
HPV- associated cancers. These findings support further 
investigation of bintrafusp alfa in patients with advanced, 
pretreated HPV- associated cancers.
BACKGROUND
Human papillomavirus (HPV) causes almost 
all cervical cancers and a large proportion 
of anogenital and oropharyngeal cancers.1 
Worldwide, approximately 630,000 new cases 
of HPV- associated malignancies are reported 
annually. Advanced HPV- associated cancers 
are often incurable and poorly palliated by 
traditional chemotherapies.2–5
Host immunity impacts HPV infection 
and progression to cancer,6 and several 
immune- related pathways are linked to HPV- 
associated cancers.6 7 Transforming growth 
factor β (TGF-β), a pleiotropic cytokine that 
suppresses tumor growth and inhibits tumor- 
promoting inflammation in the premalig-
nant state, is associated with tumor growth, 
evasion of immune surveillance, invasion, 
and metastasis in the advanced cancer state.8 
Genome- wide association studies showed that 
the TGF-β pathway is associated with cervical 
cancer and HPV- positive squamous cell 
carcinoma of the head and neck (SCCHN), 
and TGF-β receptor I is significantly over-
expressed in these cancers compared with 
benign tissue.6 Another study found a posi-
tive correlation between HPV infection and 
TGF-β levels in saliva and serum of patients 
with oral squamous cell carcinoma (SCC).9 
E6 and E7 oncoproteins induce activation of 
the TGF-β promotor in cervical cancer cell 
lines,10 and RNAseq analysis of HPV- positive 
oropharyngeal SCC showed that patients with 
poor survival were enriched for a TGF-β gene 
signature and had elevated levels of HPV- E6 
protein expression.11 A recent study found 
that patients with HPV- positive SCCHN with a 
specific polymorphism in TGFB1 had signifi-
cantly better overall and disease- specific 
survival compared with patients with the 
common genotype and that a similar benefit 
was not seen in patients with HPV- negative 
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SCCHN cancers.12 Hence, dysregulation of the TGF-β 
pathway may play a critical role in HPV- mediated carcino-
genesis, and this pathway may be a potential therapeutic 
target.
Results from two phase 1b, three phase 2 (including one 
basket trial), and one randomized phase 3 study showed 
objective response rates of 12%–24% for single- agent 
programmed cell death 1 (PD-1) inhibitors (nivolumab 
and pembrolizumab) in HPV- associated anal, cervical, 
and head and neck cancers.13–18 Studies in murine SCC 
models showed that anti- PD-1 therapy rarely led to 
complete regression, but adding anti- TGF-β synergistically 
enhanced antitumor responses.19 The synergy was partly 
driven by anti- TGF-β-mediated suppression of anti- PD-1 
resistance and by attenuating epithelial- mesenchymal 
transition and stimulating immunosurveillance.
Bintrafusp alfa (M7824) is a first- in- class bifunctional 
fusion protein composed of the extracellular domain of 
the human TGF-β receptor II (TGF-βRII or TGF-β ‘trap’) 
fused via a flexible linker to the C- terminus of each 
heavy chain of an IgG1 antibody blocking programmed 
cell death ligand 1 (anti- PD- L1). In preclinical studies, 
compared with TGF-β sequestration or anti- PD- L1 anti-
body alone, bintrafusp alfa extended survival, conferred 
long- term protective immunity, decreased regulatory 
T- cell function,20 substantially increased CD8+ T cell and 
natural killer cell infiltration, and decreased myeloid- 
derived suppressor cell infiltration within tumors.21–23 In 
a phase 1 clinical trial, bintrafusp alfa efficiently seques-
tered plasma TGF-β1, TGF-β2, and TGF-β3 and bound 
to and saturated peripheral PD- L1.24 Treatment was 
well tolerated and clinically active, producing durable 
responses in several solid tumor types. Here, we report 
pooled safety and efficacy data from the subset of patients 
with checkpoint inhibitor- naive HPV- associated cancers 
from the phase 1 (study 001) and 2 (study 012) trials of 
bintrafusp alfa.
METHODS
Study design and subjects
This is a post hoc analysis of an ongoing global, phase 1, 
open- label trial of bintrafusp alfa in patients with heavily 
pretreated advanced solid tumors and a phase 2 single- 
center trial of patients with advanced HPV- associated 
cancers. All patients with HPV- associated cancers from 
study 001 were from prospectively defined cohorts 
(cervical, SCCHN) or from the prospectively defined 
dose- escalation cohort, and the HPV population of study 
012 was also prospectively planned. The primary results 
of the dose- escalation part (which included three patients 
from this analysis; online supplemental table S1) have 
been previously reported.24 Full inclusion and exclusion 
criteria for both studies are listed in the online supple-
mental file.
The studies were conducted in accordance with all 
applicable regulatory requirements, and the protocols 
were approved by the institutional review boards of the 
participating institutions. International standards of 
Good Clinical Practice and the Declaration of Helsinki 
were followed. Each patient provided written informed 
consent before study enrollment. A full list of investiga-
tors and sites is listed in online supplemental table S2.
Procedures
Clinical procedure and assessments
Patients received bintrafusp alfa via 1- hour intravenous 
infusion every 2 weeks at doses of 0.3–30 mg/kg in the 
dose- escalation part of the phase 1 trial or at the recom-
mended phase 2 dose of 1200 mg in the expansion part 
and the phase 2 trial.
The planned treatment duration was 1 year (for the 
phase 1 trial) or until progressive disease, unaccept-
able toxicity, or study withdrawal. Longer treatment and 
treatment past progression were permitted if clinically 
justified.
The primary objective of this post hoc analysis is to 
evaluate the efficacy of bintrafusp alfa monotherapy in 
checkpoint inhibitor- naive HPV- associated cancers. An 
exploratory analysis in checkpoint inhibitor- refractory 
HPV- associated cancers is also reported. Patients in both 
studies underwent tumor assessment scans every 6 weeks 
for the first 12 months and then every 12 weeks unless clin-
ical symptoms warranted earlier imaging. Radiographic 
response was assessed by the investigator using Response 
Evaluation Criteria in Solid Tumors V. 1.1 (RECIST V.1.1) 
and reviewed by an independent radiologist at the inves-
tigational site for the dose- escalation part of the phase 1 
study and the phase 2 study. A central facility reviewed 
radiographic responses for patients in the expansion part 
of the phase 1 study. Responses were confirmed by repeat 
assessment after a minimum of 4 weeks. Total clinical 
response rate was defined as the number of patients with 
best overall response (BOR) of complete response (CR) 
or partial response (PR) per RECIST V.1.1, or who experi-
enced delayed response following initial pseudoprogres-
sion. The duration of response was defined as the time 
from initial response to the time of disease progression 
or death. Safety was evaluated according to the Common 
Terminology Criteria for Adverse Events versions 4.03 
and 5 in the phase 1 and 2 studies, respectively.
HPV status
For determination of HPV- positive disease, prior docu-
mentation of tumor sample HPV status was accepted. For 
patients without documentation in the dose- escalation 
cohort of the phase 1 or phase 2 study, HPV status was 
determined by PCR, when fresh or archived tissue was 
available, using the cobas 4800 HPV Test (Roche Molec-
ular Systems) or BD Onclarity HPV Assay (Becton Dick-
inson). In the expansion cohort of the phase 1 study, 
HPV status was determined by RNA sequencing using 
formalin- fixed paraffin- embedded (FFPE) tissue samples 
according to standard protocols, with HPV content in 
each sample assessed as the fraction of reads mapping to 
any papillomavirus genome.
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Laboratory correlates
Immune responses to HPV were analyzed in patients from 
the dose- escalation cohort of the phase 1 study and the phase 
2 study as previously described.25 Briefly, HPV- specific T- cell 
responses were assessed in cryopreserved peripheral blood 
mononuclear cells (PBMCs) isolated before and 2 weeks 
after one and/or three cycles of bintrafusp alfa, by intra-
cellular cytokine staining following in vitro stimulation with 
a mixture of overlapping 15- mer peptide pools encoding 
HPV-16 E6 and E7. Peptide pools encoding human leuko-
cyte antigen and CEFT (a mixture of peptides of cytomeg-
alovirus, Epstein- Barr virus, influenza, and tetanus toxin) 
served as negative and positive controls, respectively. The 
absolute number of viable CD4+ or CD8+ T lymphocytes 
producing cytokine or positive for the degranulation 
marker CD107a at the end of expansion was calculated per 
1×106 cells plated at the start of the stimulation assay. This 
calculation takes into account not only the percentage but 
also the total number of viable antigen- specific CD4+ and 
CD8+ T cells expanded in the stimulation assay.
Finally, PD- L1 expression was detected by immuno-
histochemistry staining of FFPE tumor tissue using an 
anti- PD- L1 antibody clone 73-10 (Dako PD- L1 IHC 73-10 
pharmDx; Dako, Carpinteria, California, USA). PD- L1 
expression was measured on tumor cells and on cells 
of the tumor microenvironment (TME). Data herein 
are reported based on the percentage of tumor cells 
expressing PD- L1. A threshold of 1% was used to charac-
terize tumors as either PD- L1 positive (≥1%) or negative 
(<1%).
Outcomes
The primary endpoint of the dose- escalation part of 
the phase 1 trial was safety. The primary endpoint of 
the expansion part of the phase 1 trial and the phase 2 
trial was the BOR according to RECIST V.1.1, and the 
secondary endpoint was safety. Progression- free survival 
(PFS), overall survival (OS), duration of response, and the 
relationship of immune responses to clinical responses 
were exploratory endpoints for the phase 1 trial and 
secondary endpoints for the phase 2 trial (except for 
immune response).
Statistical analysis
The sample size for the dose- escalation component of the 
trial followed a 3+3 design for dose- finding studies. Enroll-
ment into multiple expansion cohorts was opened after 
the recommended phase 2 dose of bintrafusp alfa had 
been established (1200 mg intravenously every 2 weeks). 
All patients with HPV- associated cancers who received 
bintrafusp alfa were included in the safety and full analysis 
sets described here. Safety and tolerability were analyzed 
using descriptive statistics. The durations of PFS, response, 
and OS were analyzed using the Kaplan- Meier method.
RESULTS
From January 26, 2016, to August 21, 2017, 17 patients 
with advanced HPV- associated cancer (cervical (n=10), 
anal (n=4), p16+ SCCHN (n=3)) were enrolled in the 
dose- escalation cohort, and 26 patients with advanced 
cervical cancer (n=15) or HPV- positive SCCHN (n=11) 
were enrolled into the expansion part of the phase 1 
study. Overall, 14 patients with SCCHN and confirmed 
HPV- positive status from the phase 1 study are included 
in this analysis. The results for the overall SCCHN cohort 
are reported in a separate manuscript.26 HPV status for 
all patients was determined post hoc and not required for 
enrollment. Thirty- six patients were enrolled in the phase 
2 study from February 27, 2018, to July 16, 2019, including 
20 patients with checkpoint inhibitor- refractory disease.
Fifty- nine patients, including 43 from the phase 1 trial 
and 16 from the phase 2 trial, with checkpoint inhibitor- 
naive disease were included in this post hoc analysis. At 
the phase 1 analysis cutoff of April 17, 2019, and phase 2 
analysis cutoff of October 4, 2019, the median duration of 
bintrafusp alfa treatment among all patients in this post 
hoc analysis was 3.9 months (range, 0.5–29.9 months) 
and 3.0 months (range, 0.5–7.8 months), respectively. 
Treatment was ongoing in 7 of 59 checkpoint inhibitor- 
naive patients (11.9%). The primary reasons for treat-
ment discontinuation were disease progression (n=35), 
adverse events (n=8), non- treatment- related death (n=1), 
withdrew consent (n=5), investigator decision (n=1), lack 
of clinical benefit/patient decision (n=1), and comple-
tion of treatment (n=1).
Baseline demographic data and disease characteristics 
are summarized in table 1. Fifty- two patients (88.1%) had 
confirmed HPV- positive tumors, three patients (5.1%, all 
with cervical cancer) had HPV- negative disease (by RNA 
sequencing), and HPV status was missing or not available 
for four patients (6.8%, all with cervical cancer). Although 
the phase 2 study primarily enrolled female patients from 
a single center in the USA (National Cancer Institute) 
and enrolled patients with many more different tumor 
types than in the phase 1 study, age and Eastern Cooper-
ative Oncology Group performance status were similar in 
both studies.
Between the two studies, 5 patients (8.5%) with check-
point inhibitor- naive disease had a confirmed CR and 13 
patients (22%) had a confirmed PR, as determined by 
investigator- assessed RECIST V.1.1 (table 2, figure 1A, 
online supplemental figure S1). The confirmed objective 
response rate was 30.5% (95% CI, 19.2 to 43.9) in the 
full analysis set. Patients with confirmed CRs had cervical 
(n=2), anal (n=1), vaginal (n=1), and rectal SCC (n=1) 
cancers; the confirmed PRs occurred in four patients 
with SCCHN, eight with cervical cancer (including one 
patient with neuroendocrine cervical cancer), and one 
with anal cancer (figure 1B, online supplemental figure 
S2). Treatment responses occurred irrespective of PD- L1 
expression in the phase 1 study (online supplemental 
figure S3). The response durations ranged from 2.8+ to 
30.4 months (median, 19.1 months (95% CI, 9.6 to 27.4)); 
as of the data cut- off, 5 responses have lasted >18 months, 
and 11 responses (including one delayed response) were 
ongoing.
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In addition, three patients with checkpoint inhibitor- 
naive disease (cervical (n=1) and SCCHN (n=2)) had 
delayed PRs after initial disease progression that lasted 
14.6, 6.1, and 15.9+ months, respectively (figure 1A, 
online supplemental figure S1), resulting in a total clin-
ical response rate of 35.6% in the full analysis set (table 2). 
Additionally, one patient with checkpoint inhibitor- naive 
disease (vulvar cancer) had an unconfirmed CR but died 
of an unrelated medical illness (osteoporotic hip fracture 
with resulting sequela) prior to confirmation of response. 
The total clinical response rates were ≥30% for most HPV- 
associated tumor types, including cervical cancer (10/33 
(30%)), anal cancer (2/6 (33%)), and SCCHN (6/15 
(40%)). In addition, confirmed responses were seen in 
Table 1 Baseline patient characteristics
Study 001 (n=43) Study 012 (n=16) Full analysis set (N=59)
Sex
  Male 14 (32.6) 1 (6.3) 15 (25.4)
  Female 29 (67.4) 15 (93.8) 44 (74.6)
Age, median (IQR), years 56.0 (49.0–64.0) 57.6 (44.0–63.6) 56.0 (48.3–64.0)
  <65 33 (76.7) 13 (81.3) 46 (78.0)
  ≥65 10 (23.3) 3 (18.8) 13 (22.0)
Geographic region
  North America 23 (53.5) 16 (100) 39 (66.1)
  Europe 13 (30.2) 0 13 (22.0)
  Asia Pacific 7 (16.3) 0 7 (11.9)
Time since first diagnosis, median (range), months 34.2 (5.4–125.5) 31.5 (9.4–80.5) 34.2 (5.4–125.5)
No of prior anti- cancer therapies
  1 14 (32.6) 6 (37.5) 20 (33.9)
  2 13 (30.2) 2 (12.5) 15 (25.4)
  ≥3 16 (37.2) 8 (50.0) 24 (40.7)
Type of previous anti- cancer therapy for metastatic or locally advanced disease
  Cytotoxic therapy 43 (100) 16 (100) 59 (100)
  Monoclonal antibodies 27 (62.8) 6 (37.5) 33 (55.9)
  Immunotherapy other than anti- PD- (L)1* 3 (7.0) 1 (6.3) 4 (6.8)
ECOG performance status
  0 21 (48.8) 8 (50) 29 (49.2)
  1 22 (51.2) 8 (50) 30 (50.8)
Primary tumor type
  Cervical 25 (58.1) 8 (50.0) 33 (55.9)
  SCCHN 14 (32.6) 1 (6.3) 15 (25.4)
  Anal 4 (9.3) 2 (12.5) 6 (10.2)
  Rectal SCC 0 2 (12.5) 2 (3.4)
  Vaginal 0 1 (6.3) 1 (1.7)
  Vulvar 0 1 (6.3) 1 (1.7)
  Neuroendocrine cervical 0 1 (6.3) 1 (1.7)
Primary HPV status at screening†
  Positive 36 (83.7) 16 (100) 52 (88.1)
  Negative 3 (7.0) 0 3 (5.1)
  Unknown 4 (9.3) 0 4 (6.8)
Data are n (%), unless otherwise specified.
*All four patients received adoptive T- cell transfer.
†In the dose- escalation cohort, when tissue was available, HPV status was determined by PCR using the cobas 4800 HPV test (Roche 
Molecular Systems). In the dose- expansion cohort, HPV status was determined by RNA sequencing or the investigators.
ECOG, Eastern Cooperative Oncology Group; HPV, human papillomavirus; IQR, interquartile range; PD-1, programmed cell death protein 1; 
PD- L1, programmed cell death ligand 1; SCC, squamous cell carcinoma; SCCHN, SCC of the head and neck.
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3 of 5 (60%) rare tumor types, including vaginal (1/1 
(100%)), rectal SCC (1/2 (50%)), and neuroendocrine 
cervical (1/1 (100%)) cancer. More than half (31/59 
(53%)) of all patients had reduction in tumor diameters 
with bintrafusp alfa treatment, and 23 patients (39%) 
had tumor diameter reductions of >30% (figure 1B, 
online supplemental figure S2). The disease control rate 
according to RECIST V.1.1 was 44.1% in the full analysis 
set (table 2).
The median PFS was 2.8 months in the full analysis 
set (95% CI, 1.4 to 5.5 months; table 2, figure 2A). The 
median OS was not reached (95% CI, 8.6 months to 
not reached) in the full analysis set (table 2, figure 2B). 
Kaplan- Meier estimated proportions of patients with PFS 
and OS at different time points from baseline are shown 
in table 2. Of 59 patients in the full analysis set, 34 (58%) 
were alive at the cutoff, after a median follow- up of 9.2 
months.
Twenty patients refractory to immune checkpoint inhib-
itors were also enrolled and were not part of the full anal-
ysis set. The confirmed objective response rate for this 
group was 10% (95% CI, 1.2% to 31.7%; 1 CR (anal) and 
1 PR (SCCHN)), with both responses ongoing and with 
durations of 1.4+ and 3.7+ months. Neither patient had 
received checkpoint inhibitor therapy for several months 
prior to enrolling, suggesting that these responses were 
not due to prior checkpoint therapy. The median PFS 
and OS for patients with checkpoint inhibitor- refractory 
disease was 1.4 months (95% CI, 1.3 to 3.3 months) and 
3.4 months (2.3 months to not reached), respectively.
An evaluation of immune responses to HPV-16 in 
patients who had a BOR to bintrafusp alfa therapy of 
Table 2 Summary of tumor response and survival data
Study 001 (n=43) Study 012 (n=16) Full analysis set (N=59)
Confirmed BOR, n (%)
  CR 3 (7.0) 2 (12.5) 5 (8.5)
  PR 9 (20.9) 4 (25.0) 13 (22.0)
  SD 6 (14.0) 2 (12.5) 8 (13.6)
  PD 20 (46.5) 7 (43.8) 27 (45.8)
  Not evaluable 5 (11.6) 1 (6.3) 6 (10.2)
  Delayed PR* 3 (7.0) 0 3 (5.1)
Confirmed ORR, n (%; 95% CI) 12 (27.9; 15.3 to 43.7) 6 (37.5; 15.2 to 64.6) 18 (30.5; 19.2 to 43.9)
Disease control, n (%; 95% CI)† 18 (41.9; 27.0 to 57.9) 8 (50.0; 24.7 to 75.3) 26 (44.1; 31.2 to 57.6)
Total clinical response rate, n (%; 
95% CI)‡
15 (34.9; 21.0 to 50.9) 6 (37.5; 15.2 to 64.6)§ 21 (35.6; 23.6 to 49.1)§
Duration of response, median, 
months (95% CI)
19.1 (4.2 to 27.4) NR (4.2 to NR) 19.1 (9.6 to 27.4)
KM- estimated PFS, median, 
months (95% CI)
2.8 (1.4 to 4.6) 3.3 (1.4 to NR) 2.8 (1.4 to 5.5)
KM- estimated PFS rate, % (95% 
CI)
  6 months 31.0 (17.8 to 45.0) 43.8 (19.8 to 65.6) 34.2 (22.4 to 46.4)
  12 months 26.2 (14.1 to 40.0) 29.2 (9.6 to 52.3) 27.0 (16.3 to 38.9)
  18 months 23.3 (11.8 to 37.0) – 24.3 (13.8 to 36.4)
KM- estimated OS, median, months 
(95% CI)
16.2 (7.1 to NR) NR (3.7 to NR) NR (8.6 to NR)
KM- estimated OS rate, % (95% CI)
  6 months 73.7 (57.5 to 84.5) 72.1 (41.5 to 88.6) 73.1 (59.4 to 82.9)
  12 months 56.5 (40.1 to 70.0) 72.1 (41.5 to 88.6) 58.8 (44.3 to 70.8)
  18 months 48.8 (32.8 to 63.0) – 51.4 (36.5 to 64.3)
Data are according to investigator- assessed RECIST V.1.1.
*Due to confirmed PD before onset of response, these patients did not meet response criteria by RECIST V.1.1.
†CR plus PR plus SD.
‡ORR per RECIST V.1.1 plus delayed PR after initial disease progression.
§One additional patient with a vulvar tumor had an unconfirmed CR.
BOR, best overall response; CR, complete response; HPV, human papillomavirus; KM, Kaplan- Meier; NR, not reached; OS, overall survival; 
PD, progressive disease; PFS, progression- free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, 
stable disease.
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stable disease or better versus patients who had a BOR of 
progressive disease was performed in the dose- escalation 
cohort and phase 2 study patients after one and/or three 
cycles of bintrafusp alfa. Sufficient PBMCs to test for 
HPV-16- specific T- cell responses before and after treat-
ment were available from 33 patients; 31 patients were 
evaluated before and after cycle 1, and 23 patients were 
evaluated before and after cycle 3 according to PBMC 
availability (online supplemental table S3). HPV- specific 
T cells were calculated as the absolute number of CD4+ or 
CD8+ T cells producing cytokine or positive for CD107a 
(lysosome- associated membrane protein 1, a functional 
marker of T- cell and natural killer cell activity) after 
expansion per 1×106 PBMCs plated at the start of the 
stimulation assay, which takes into account not only the 
percentage of positive lymphocytes, but also the number 
of total antigen- specific T cells that are expanded. In 
this analysis, after cycle 1, 9 of 14 patients (64.3%) 
with stable disease or better developed HPV-16- specific 
T cells versus 4 of 17 (23.5%) with progressive disease 
(p=0.03; online supplemental table S3). After cycle 3, 9 
of 12 patients (75%) with stable disease or better devel-
oped HPV-16- specific T cells versus 6 of 11 (54.5%) with 
progressive disease (p=0.40; online supplemental table 
S3). Patients who had a BOR of stable disease or better 
had, on average, sixfold more HPV- specific T cells that 
produced cytokines or were positive for CD107a after 
cycle 1 (p=0.04) and cycle 3 (p<0.001) than patients who 
had a BOR of progressive disease (online supplemental 
figure S4). Trends in differences between responders 
and non- responders were also noted when HPV- specific 
T cells were quantified as a percentage of viable lympho-
cytes; using a twofold change as a cutoff, 11 of 14 patients 
(78.6%) with a BOR of stable disease or better, and 8 of 17 
patients (47.1%) with progressive disease had an increase 
in HPV- specific T cells after one cycle of bintrafusp alfa.
Treatment- related adverse events (TRAEs) occurred 
in 83.1% (49/59) patients (table 3). The most common 
Figure 1 Clinical responses to bintrafusp alfa. (A) 
Percentage change in tumor diameters over time per 
investigator- assessed RECIST V.1.1 in the full analysis set. 
(B) Best percentage change in target lesions from baseline 
by cancer type as assessed by the investigators in the full 
analysis set. Data from three patients are missing due to 
lack of post- baseline tumor assessments. aIncludes two 
patients with rectal SCC tumors and one patient (each) 
with neuroendocrine cervical, vaginal, and vulvar tumors 
from study 012. Additional details can be found in online 
supplemental figure S1B). bDelayed PR. Due to confirmed 
progressive disease (PD) before onset of response, these 
patients did not meet response criteria by RECIST V.1.1. 
cPatient had a PR of target lesions but had progression of 
a non- target lesion requiring radiotherapy to the isolated 
non- target lesion (best response of PD by RECIST V.1.1). 
dPatients had disease limited to lymph nodes, which shrank 
to <1 cm in the short axis and did not completely disappear 
(best response of CR by RECIST V.1.1). ePatient had a CR but 
died of an unrelated medical illness (osteoporotic hip fracture 
with resulting sequela) prior to confirmation of response by 
investigator. CR, complete response; PR, partial response; 
SCC, squamous cell carcinoma; SCCHN, squamous cell 
carcinoma of the head and neck.
Figure 2 Kaplan- Meier analyses of PFS and OS. PFS 
according to investigator- assessed RECIST V.1.1 (A) and OS 
(B) in the full analysis set (purple), study 001 (pink), and study 
012 (cyan). Marks on the curve indicate patients who were 
censored. OS, overall survival; PFS, progression- free survival.
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Table 3 TRAEs occurring at any grade in ≥5% of patients or grade ≥3 in any patient and any AEs of special interest (AESIs) 
from the full analysis set
Study 001 (n=43) Study 012 (n=16) Full analysis set (N=59)
Any grade Grade 3 Any grade Grade 3 Any grade Grade 3
Patients with any TRAE 35 (81.4) 11 (25.6) 14 (87.5) 5 (31.3) 49 (83.1) 16 (27.1)
  Pruritus 10 (23.3) 0 5 (31.3) 0 15 (25.4) 0
  Dermatitis acneiform 7 (16.3) 0 5 (31.3) 0 12 (20.3) 0
  Keratoacanthoma 9 (20.9) 2 (4.7) 0 0 9 (15.3) 2 (3.4)
  Hypothyroidism 7 (16.3) 1 (2.3) 2 (12.5) 0 9 (15.3) 1 (1.7)
  Rash maculopapular 6 (14.0) 0 3 (18.8) 0 9 (15.3) 0
  Anemia 4 (9.3) 1 (2.3) 5 (31.3) 3 (18.8) 9 (15.3) 4 (6.8)
  Fatigue 2 (4.7) 0 5 (31.3) 1 (6.3) 7 (11.9) 1 (1.7)
  Stomatitis 3 (7.0) 0 2 (12.5) 0 5 (8.5) 0
  Rash macular 3 (7.0) 1 (2.3) 0 0 3 (5.1) 1 (1.7)
  Alanine aminotransferase increased 2 (4.7) 0 1 (6.3) 0 3 (5.1) 0
  Aspartate aminotransferase increased 2 (4.7) 0 1 (6.3) 0 3 (5.1) 0
  Asthenia 3 (7.0) 0 0 0 3 (5.1) 0
  Diarrhea 2 (4.7) 0 1 (6.3) 0 3 (5.1) 0
  Epistaxis 2 (4.7) 0 1 (6.3) 0 3 (5.1) 0
  Decreased appetite 3 (7.0) 0 0 0 3 (5.1) 0
  Influenza- like illness 1 (2.3) 0 2 (12.5) 0 3 (5.1) 0
  Infusion- related reaction 2 (4.7) 0 1 (6.3) 0 3 (5.1) 0
  Mouth hemorrhage (mucosal bleeding) 0 0 3 (18.8) 0 3 (5.1) 0
  Nausea 3 (7.0) 0 0 0 3 (5.1) 0
  Colitis 1 (2.3) 1 (2.3) 1 (6.3) 0 2 (3.4) 1 (1.7)
  Pneumonitis 2 (4.7) 1 (2.3) 0 0 2 (3.4) 1 (1.7)
  Hypokalemia 1 (2.3) 1 (2.3)* 0 0 1 (1.7) 1 (1.7)*
  Squamous cell carcinoma of skin 1 (2.3) 1 (2.3) 0 0 1 (1.7) 1 (1.7)
  γ-glutamyltransferase increased 1 (2.3) 1 (2.3) 0 0 1 (1.7) 1 (1.7)
  Diabetic ketoacidosis 1 (2.3) 1 (2.3) 0 0 1 (1.7) 1 (1.7)
  Neutrophil count decreased 0 0 1 (6.3) 1 (6.3) 1 (1.7) 1 (1.7)
  Hyperglycemia 0 0 1 (6.3) 1 (6.3) 1 (1.7) 1 (1.7)
  Cystitis non- infective 1 (2.3) 1 (2.3) 0 0 1 (1.7) 1 (1.7)
  Impaired gastric emptying 1 (2.3) 1 (2.3) 0 0 1 (1.7) 1 (1.7)
  Pleural effusion 1 (2.3) 1 (2.3) 0 0 1 (1.7) 1 (1.7)
  Upper gastrointestinal hemorrhage 0 0 1 (6.3) 1 (6.3) 1 (1.7) 1 (1.7)
  Hyperkeratosis follicularis et parafollicularis 1 (2.3) 1 (2.3) 0 0 1 (1.7) 1 (1.7)
Any AESIs
  Skin lesions† 12 (27.9) 4 (9.3) 0 0 12 (20.3) 4 (6.8)
Data are n (%) of the safety set.
*Grade 3 hypokalemia progressed to grade 4.
†Includes MedDRA V.2.0.0 and 21.1 preferred terms squamous cell carcinoma of skin, basal cell carcinoma, keratoacanthoma, 
hyperkeratosis, actinic keratosis, lip squamous cell carcinoma, and Bowen’s disease. Not included in the table were five patients (8%) in 
study 012 who were noted by the MedDRA System Organ Class of Neoplasms benign, malignant, and unspecified (including cysts and 
polyps), but the MedDRA preferred term was not captured (although it was deemed to be related to keratoacanthoma).
AESI, adverse event of special interest; MedDRA, Medical Dictionary for Regulatory Activities; SCC, squamous cell carcinoma; TRAE, 
treatment- related adverse event.
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TRAE was pruritus, which occurred in 15 patients 
(25.4%). Grade 3 TRAEs occurred in 16 patients (27.1%); 
the most common was anemia, which occurred in four 
patients (6.8%). A patient who had grade 3 gastroparesis 
developed asymptomatic grade 3 hypokalemia, which 
worsened to grade 4 (one grade 4 event (1.7%)) and led 
to permanent study treatment discontinuation. This was 
medically managed without corticosteroids, gradually 
improved, and resolved completely within 2 months. No 
treatment- related deaths occurred.
Seven patients (11.9%) discontinued bintrafusp alfa 
due to TRAEs (colitis, gastroparesis (described above), 
infusion- related reaction, non- infective cystitis, pneumo-
nitis, acneiform dermatitis, and psoriasiform dermatitis). 
Treatment- related infusion- related reactions occurred in 
three patients (5.1%). Adverse events of special interest, 
including potential TGF-β-related skin lesions, which 
included Medical Dictionary for Regulatory Activities 
V.21.0 preferred terms of keratoacanthoma, SCC of skin, 
basal cell carcinoma, hyperkeratosis, actinic keratosis, 
lip SCC, and Bowen’s disease, occurred in 12 patients 
(27.9%) (table 3, online supplemental table S4). These 
skin lesions were well managed with observation or local 
therapy (cryotherapy or excision) and did not require any 
patient to discontinue treatment. Thirty- eight patients 
(64.4%) in the full analysis set experienced treatment- 
emergent bleeding; nine patients (15.3%) had grade 3 
bleeding events, and no patients had grade 4 or 5 events.
DISCUSSION
Safety and efficacy data are presented from a post 
hoc combined analysis of 59 patients with advanced 
pretreated, checkpoint inhibitor- naive HPV- associated 
cancers who were enrolled in global phase 1 and 2 studies 
of bintrafusp alfa. Responses to bintrafusp alfa occurred 
in patients with several different types of HPV- associated 
cancers (SCCHN, cervical (including neuroendocrine), 
anal, vaginal, vulvar, rectal SCC). These responses were 
durable, ranging from 2.8+ to 30.4 months. While 
responses were observed irrespective of PD- L1 expres-
sion, given that PD- L1 expression was determined from 
archival samples, the age of the sample or previous 
therapy may have influenced the results.
Historical data observed with PD-1 inhibitors pembroli-
zumab and nivolumab in patients with HPV- associated 
cancers demonstrated objective response rates of 12%–
24% and median OS of 7.5–11.5 months.13–18 Based on 
safety and efficacy data from these phase 1 and phase 2 
studies, bintrafusp alfa in patients with advanced HPV- 
associated malignancies compares favorably with histor-
ical data of these PD-1 inhibitors. Survival also seems to 
be longer, with a median OS not reached after 18 months 
of follow- up; however, data from these studies cannot be 
compared directly due to differences in study design, 
eligibility criteria, and patient characteristics. To increase 
the response rates in HPV- associated cancers and other 
solid tumors, checkpoint inhibitors are being evaluated 
in combination with other novel immunotherapies, and 
our findings may support TGF-β as a therapeutic target in 
HPV- associated cancers.6
The safety profile of bintrafusp alfa was consistent with 
historically observed safety profiles of bintrafusp alfa in 
other tumor types. The severity and type of immune- 
related adverse events observed with bintrafusp alfa 
were also comparable to those observed with PD- (L)1 
inhibitors.13 16 27 Additional toxicities that were seen with 
bintrafusp alfa that have not been described with PD- (L)1 
inhibitors included keratoacanthomas and low- grade 
mucosal bleeding (eg, epistaxis, gingival bleeding). Study 
limitations from this combined analysis include the post 
hoc nature of this analysis and absence of a comparator 
treatment arm. Patients were selected for this analysis 
based on HPV- associated disease. Therefore, this analysis 
does not provide any conclusions about whether HPV- 
positive status is an independent biomarker predictive of 
response in all HPV- associated cancers; however, in the 
SCCHN expansion cohort, response rates in those with 
HPV- positive disease (determined by viral RNA detected 
in tumor samples) were 33% (3 of 9 patients) compared 
with 5% (1 of 22) in those without evidence of HPV infec-
tion.26 Finally, the small numbers of patients with rare 
tumors (cervical neuroendocrine, anal, vaginal, vulvar, 
rectal SCC) limits conclusions for safety and efficacy in 
these tumors.
In conclusion, targeting TGF-β and PD- L1 bifunctionally 
with bintrafusp alfa is a promising therapeutic approach 
for patients with HPV- associated cancers. Bintrafusp alfa 
had a manageable safety profile and resulted in an objec-
tive response rate of 30.5% in patients with pretreated 
checkpoint inhibitor- naive HPV- associated cancers, with 
clinical activity observed in patients who were refrac-
tory to PD- (L)1 treatment. Bintrafusp alfa continues in 
a range of phase 2 studies, including studies of patients 
with HPV- associated malignancies.
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